A recent analysis of data is providing insight into the use of aspirin for preeclampsia prevention among women with prepregnancy obesity, hypertension, or diabetes.
This article was originally published on HCPLive.com.
New research is describing the current rate of aspirin use for preeclampsia prevention among pregnant women.
Led by Joel G. Ray, MD, Department of Medicine, St Michael’s Hospital, the study, which comes on the heels of recent USPSTF recommendations on aspirin use, suggests aspirin use was prevalent among 3.2% of those without prepregnancy diabetes, obesity, or hypertension and use among women with these comorbidities ranged from 6.9-27.6%.
Women from Ontario, Canada with a hospital live birth or stillbirth at 23 weeks’ gestation or greater from April 2018 - December 2020 were included in the study. The data were obtained from the Better Outcomes Registry (BORN).
In BORN, all hospitalized birth data were collected by health care professionals from charts, clinical forms, and patient interviews and entered into the system. It included demographics, clinical details, and a yes or no answer for “aspirin taken daily for preeclampsia prevention, any time after 12 weeks’ gestation.”
Rates of aspirin use overall and those with diabetes, obesity, or hypertension were calculated using 95% confidence intervals.
A total of 371,237 births were included during the study period. Pregnant women with diabetes, obesity, or hypertension were older, had a higher body mass index, more preterm birth, and a longer hospital length of stay, in contrast to those without any of the conditions.
Moreover, women with diabetes, obesity, or hypertension (n = 77,582) comprised 20.9% of the sample population. Aspirin was used by 3.2% (95% CI, 3.2% - 3.3%) of women without diabetes, obesity, or hypertension.
Data show the rate of aspirin use was 17.2% (95% CI, 16.2% - 18.2%) in women with diabetes, 6.9% (95% CI, 6.7% - 7.1%) in women with obesity, and 27.6% (95% CI, 26.2% - 29.0%) in women with hypertension.
Further, the numbers on aspirin use was 22.2% (95% CI, 20.5% - 24.0%) in women with diabetes and obesity, 36.6% (95% CI, 31.9% - 41.6%) in women with diabetes and hypertension, and 32.3% (95% CI, 30.2% - 34.5%) in women with obesity and hypertension. The rate was 38.8% (95% CI, 32.9% - 44.9%) in women with all 3 factors.
“For the 2021 USPSTF recommendations to be more influential, more data are needed to characterize barriers for aspirin adoption among suitable women at the patient and practitioner level, and additional knowledge translation initiatives developed,” Ray and colleagues concluded.
The research letter, “Aspirin Use for Preeclampsia Prevention Among Women With Prepregnancy Diabetes, Obesity, and Hypertension,” was published in JAMA.